Skip to main content
Grifols S.A. logo

Grifols S.A. — Investor Relations & Filings

Ticker · GRF ISIN · ES0171996087 LEI · 959800HSSNXWRKBK4N60 MC Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2026-01-08 Board/Management Inform…
Country ES Spain
Listing MC GRF

About Grifols S.A.

https://www.grifols.com/en/home

Grifols S.A. is a global healthcare company specializing in the development, production, and marketing of plasma-derived medicines and other biopharmaceutical solutions. As a leading producer of therapies derived from human plasma, the company addresses the needs of patients with chronic, rare, and life-threatening conditions. Its core activities encompass the entire plasma value chain, from collection to the manufacturing of essential protein therapies. In addition to its primary Biopharma division, Grifols provides a comprehensive portfolio of diagnostic solutions for transfusion medicine and clinical laboratories, as well as bio supplies for pharmaceutical and research applications. The company is committed to advancing patient health and well-being through scientific innovation and high standards of quality and safety.

Recent filings

Filing Released Lang Actions
Cambio de Secretaria y Vicesecretaria del Consejo de Administración.
Board/Management Information Classification · 100% confidence The document is a formal communication from Grifols, S.A. regarding changes to the composition of its Board of Directors' secretarial roles. It explicitly mentions the appointment of new individuals to the positions of Secretary and Deputy Secretary of the Board of Directors. This falls directly under the category of board and management changes.
2026-01-08 Spanish
6-K Filing
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed with the SEC by Grifols, S.A., a foreign private issuer. It is titled 'Other Relevant Information' and dated January 8, 2026. The content announces changes in the company's Board of Directors, specifically appointments to Secretary and Vice-secretary positions. There are no financial statements, earnings data, or detailed reports included. The document is short (2443 characters) and serves as an announcement of management changes rather than a full report or detailed filing. According to the definitions, announcements of changes in the company's board or senior management fall under 'Board/Management Information' (MANG). Therefore, the correct classification is MANG with high confidence.
2026-01-08 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Grifols, S.A., pursuant to the SEC rules. It is titled 'Other Relevant Information' and dated December 16, 2025. The content describes the European Medicines Agency (EMA) issuing a Certificate of Compliance for plasma supplied by Grifols Egypt. The document is relatively short (3240 characters) and serves as an announcement of a regulatory milestone rather than a detailed financial report or management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not an annual or interim report, nor a call transcript or proxy statement. The nature of the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-12-16 English
La EMA ha emitido el Certificado de Conformidad con la legislación comunitaria para el plasma suministrado por Grifols Egypt for Plasma Derivatives.
Regulatory Filings Classification · 95% confidence The document is a formal communication from Grifols, S.A. to the Spanish securities market regulator (CNMV) under Article 227 of the Securities Market Law. It announces a specific regulatory milestone: the receipt of an EMA Certificate of Conformity for plasma from their Egyptian joint venture. As it is a regulatory announcement regarding a specific corporate development that does not fit into financial reporting, dividend, or governance categories, it is classified as a general regulatory filing.
2025-12-16 Spanish
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-12 English
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by Grifols, S.A., a foreign private issuer, reporting its third quarter 2025 financial results. It includes detailed financial data such as revenues, EBITDA, profit, cash flow, leverage ratio, and guidance for the full year. The document also mentions a conference call to discuss the quarterly results and provides a comprehensive narrative on business performance and outlook. The presence of substantive financial data and analysis for a quarter indicates this is a quarterly financial report. Form 6-K is used by foreign private issuers to report material information, often including quarterly results, to the SEC. Given the detailed quarterly financial results and analysis, this document fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a presentation but contains actual financial statements and performance metrics for the quarter.
2025-11-04 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.